Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

PubWeight™: 1.79‹?› | Rank: Top 3%

🔗 View Article (PMID 16951908)

Published in Osteoporos Int on September 02, 2006

Authors

P Vestergaard1, N R Jorgensen, L Mosekilde, P Schwarz

Author Affiliations

1: The Osteoporosis Clinic, Department of Endocrinology, Aarhus University Hospital, Aarhus C, Denmark. p-vest@post4.tele.dk

Articles citing this

The diagnosis and treatment of primary osteoporosis according to current guidelines. Dtsch Arztebl Int (2008) 2.37

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int (2008) 1.68

Indirect comparisons: a review of reporting and methodological quality. PLoS One (2010) 1.65

Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ (2009) 1.12

Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Osteoporos Int (2009) 1.01

The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci (2013) 0.94

Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2007) 0.90

Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis. Int J Womens Health (2010) 0.86

Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts. J Biol Chem (2008) 0.86

Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One (2011) 0.85

Loss of life years after a hip fracture. Acta Orthop (2009) 0.85

Fracture prevention in postmenopausal women. BMJ Clin Evid (2011) 0.84

Femoral volumetric bone density, geometry, and strength in relation to 25-hydroxy vitamin D in older men. J Bone Miner Res (2015) 0.84

The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug. Biomed Res Int (2014) 0.78

Effects of kalsis, a dietary supplement, on bone metabolism in the ovariectomized rats. J Osteoporos (2012) 0.77

A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int (2016) 0.77

Does parathyroid hormone treatment affect fracture risk or bone mineral density in patients with osteoporosis? Nat Clin Pract Rheumatol (2007) 0.76

Current and emerging therapies for the treatment of osteoporosis. J Exp Pharmacol (2010) 0.75

Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate. Calcif Tissue Int (2017) 0.75

Articles cited by this

Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95

The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med (2003) 5.45

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA (2001) 5.09

A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92

Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet (1999) 4.07

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone (2004) 2.48

Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14

Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin (2004) 2.11

The socioeconomic burden of fractures: today and in the 21st century. Am J Med (1997) 2.06

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest (1998) 1.75

Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev (2002) 1.62

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57

Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.34

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33

Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA (1998) 1.30

Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 1.19

Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev (2004) 1.18

The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin (2005) 1.11

Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int (2003) 1.10

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med (2006) 1.02

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.02

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int (2001) 0.98

Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res (2003) 0.97

Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord (2001) 0.93

Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab (1999) 0.91

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics (1998) 0.83

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int (2005) 0.82

Articles by these authors

Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 3.00

Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89

Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69

Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33

Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30

Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension (1994) 2.28

Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int (2005) 2.23

Captured by art. Science (2001) 2.21

A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab (2012) 2.16

Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord (1998) 2.07

The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr (1999) 2.03

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia (2005) 1.79

Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int (2008) 1.78

Fracture risk associated with the use of morphine and opiates. J Intern Med (2006) 1.71

Transmission of scrapie by steel-surface-bound prions. Mol Med (2001) 1.63

Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res (1993) 1.57

Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci (Lond) (1979) 1.49

Stereological considerations concerning the measurement of individual osteoid seams and resorption cavities. Bone Miner (1994) 1.47

Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47

Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest (2002) 1.46

Determinants of vitamin D status in a general population of Danish adults. Bone (2011) 1.45

Autosomal dominant osteopetrosis. Clin Orthop Relat Res (1993) 1.44

Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol (1995) 1.42

Familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf) (1994) 1.42

Stroke in relation to use of raloxifene and other drugs against osteoporosis. Osteoporos Int (2010) 1.42

Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study. J Intern Med (2012) 1.41

Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost (1995) 1.41

Polymorphisms of muscle genes are associated with bone mass and incident osteoporotic fractures in Caucasians. Calcif Tissue Int (2013) 1.40

[Costs of different intervention strategies to prevent hip fractures]. Ugeskr Laeger (1999) 1.39

Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int (1989) 1.39

Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int (2006) 1.39

Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos Int (1993) 1.39

Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut (2000) 1.33

Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) (2005) 1.30

Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy. Scand J Clin Lab Invest (2006) 1.29

The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med (2006) 1.29

The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab (1988) 1.29

Fracture risk in patients treated for hyperthyroidism. Thyroid (2000) 1.25

Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone (1990) 1.23

Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int (1993) 1.22

Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone (1999) 1.22

Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut (1991) 1.21

Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone (1994) 1.19

Parathyroid hormone and bone healing. Calcif Tissue Int (2010) 1.18

Fractures in patients with primary idiopathic hypothyroidism. Thyroid (2000) 1.17

Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone (1987) 1.17

Histomorphometric analysis of normal bone from the iliac crest. Acta Pathol Microbiol Scand A (1978) 1.16

Normal vertebral body size and compressive strength: relations to age and to vertebral and iliac trabecular bone compressive strength. Bone (1986) 1.16

Vitamin D insufficiency in Greenlanders on a westernized fare: ethnic differences in calcitropic hormones between Greenlanders and Danes. Calcif Tissue Int (2003) 1.14

Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Relat Res (1984) 1.14

Fracture risk is increased in epilepsy. Acta Neurol Scand (1999) 1.13

Tetracycline double-labeling of iliac trabecular bone in 41 normal adults. Calcif Tissue Res (1978) 1.12

Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol (2000) 1.12

Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab (2003) 1.12

Age-related changes in the biochemical properties of human cancellous bone collagen: relationship to bone strength. Calcif Tissue Int (1999) 1.12

Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone (1996) 1.11

New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability. J Med Chem (2000) 1.11

Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone (1999) 1.10

Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol (2001) 1.10

Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone (1986) 1.10

Effects of 25OHD concentrations on chances of pregnancy and pregnancy outcomes: a cohort study in healthy Danish women. Eur J Clin Nutr (2012) 1.09

Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int (2011) 1.08

Marked decrease in trabecular bone quality after five years of sodium fluoride therapy--assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone (1994) 1.07

Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner (1994) 1.07

A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone (1989) 1.06

Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int (2006) 1.06

Reduced relative risk of fractures among users of lithium. Calcif Tissue Int (2005) 1.05

An evaluation of the quantitative parameters applied in bone histology. Acta Pathol Microbiol Scand A (1978) 1.02

Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res (2003) 1.02

Low serum levels of 1.25-dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunoileal bypass for obesity. Gut (1980) 1.01

Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone (1994) 1.00

Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int (2010) 0.99

Correlation between the compressive strength of iliac and vertebral trabecular bone in normal individuals. Bone (1985) 0.99

Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int (2005) 0.99

Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int (2014) 0.99

Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue Int (1993) 0.98

A model of vertebral trabecular bone architecture and its mechanical properties. Bone (1990) 0.98

Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) (2007) 0.98

Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int (1993) 0.97

Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Metab Bone Dis Relat Res (1984) 0.97

Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone. Metab Bone Dis Relat Res (1982) 0.97

Age- and gender-related differences in vertebral bone mass, density, and strength. J Bone Miner Res (1999) 0.97

Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone (1999) 0.96

The positive effects of zinc on skeletal strength in growing rats. Bone (2001) 0.96

Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int (2005) 0.96

Osteon cross-sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia. Acta Pathol Microbiol Immunol Scand A (1982) 0.96

A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand (1978) 0.96

Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J Clin Invest (1985) 0.96

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int (2010) 0.96

Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Med Scand (1988) 0.96

Predicting human vertebral bone strength by vertebral static histomorphometry. Bone (2002) 0.95

Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) (1977) 0.95

Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol (1984) 0.95

Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol (1999) 0.94